# EDGAR Filing Document

**Accession Number:** 0001792030
**File Stem:** 0001178913-25-003251
**Filing Date:** 2025-9
**Character Count:** 8700
**Document Hash:** 1c2466c322fe1361d5d6ebf09371456f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003251.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001178913-25-003251

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250905

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IM Cannabis Corp.
- **CENTRAL INDEX KEY:** 0001792030
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40065
- **FILM NUMBER:** 251295001

**BUSINESS ADDRESS:**
- **STREET 1:** KIBBUTZ GLIL YAM
- **CITY:** CENTRAL DISTRICT
- **STATE:** L3
- **ZIP:** 4690500
- **BUSINESS PHONE:** 416-256-4202

**MAIL ADDRESS:**
- **STREET 1:** KIBBUTZ GLIL YAM
- **CITY:** CENTRAL DISTRICT
- **STATE:** L3
- **ZIP:** 4690500

------

**UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> Washington, D.C. 20549<br>

**Form 6-K**

<br> **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**<br> **UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **<u>September 2025</u>**

Commission File Number: **<u>001-40065</u>**

<br> <u>**IM Cannabis Corp.**</u><br> (Exact Name of Registrant as Specified in Charter)<br>**<u>3606 – 833 Seymour Street, Vancouver, British Columbia V6B 0G4</u>**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F ☐

------

#### CONTENTS
On September 5, 2025, IM Cannabis Corp. (the "Company") issued a press release titled: "IM Cannabis Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement". A copy of this press release is furnished herewith as Exhibit 99.1.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File No. [333-289571](https://www.sec.gov/Archives/edgar/data/1792030/000117891325002865/zk2533632.htm) and [333-288346](https://www.sec.gov/Archives/edgar/data/1792030/000117891325002247/zk2533384.htm)) filed with the Securities and Exchange Commission to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit No.** |  |
| [99.1](exhibit_99-1.htm) | [Press Release dated September 5, 2025, titled "IM Cannabis Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement".](exhibit_99-1.htm) <br>|

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **IM CANNABIS CORP.** | **IM CANNABIS CORP.** |
|  |  | (Registrant) | (Registrant) |
| Date: | September 5, 2025 | By: | /s/Oren Shuster |
|  |  | Name: | Oren Shuster |
|  |  | Title: | Chief Executive Officer and Director |

---

------

## Exhibit 99.1

------

<u>**Exhibit 99.1**</u><br>

#### IM Cannabis Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement
TORONTO and GLIL YAM, Israel, September 5, 2025/CNW/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "**Company**", "**IM Cannabis**", or "**IMC**"), a leading medical cannabis company with operations in Israel and Germany, today announced that it received notice from Nasdaq on September 4, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market.

#### About IM Cannabis Corp.

The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

#### Cautionary Note Regarding Forward-Looking Statements
*This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "**forward-looking statements**"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.*

*The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus (collectively, the "**Group**") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations;the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the Company's inability to realize upon the stated efficiencies and synergies of the Company as a global organization with domestic expertise in Israel and Germany; the Company's inability to realize upon its retail presence, distribution capabilities and data-driven insights; the Company's ability to continue to comply with Nasdaq's continued listing requirements and its ability to execute its business strategy; and the risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report on Form 20-F dated March 31, 2025, which is available on the Company's issuer profile on SEDAR+ at <u>www.sedarplus.ca</u> and Edgar at <u>www.sec.gov/edgar</u>. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.*

#### Company Contact:
Oren Shuster, CEO

IM Cannabis Corp.

+972-77-3603504

<u>info@imcannabis.com</u>

------